Celsion Corporation Announces Liver Cancer Abstract Accepted for Oral Presentation at 2008 Society of Interventional Radiology Conference

CELSION CORPORATION (AMEX: CLN) today announced that a ThermoDox Phase I liver cancer clinical abstract has been accepted for oral presentation at the 2008 Society of Interventional Radiology (SIR) conference. The SIR is hosting this Annual Scientific Meeting in Washington, DC from March 15th to 20th, 2008. This annual meeting provides advances in research, new devices, world-renowned presenters and training fundamentals for medical professionals in the non-surgical field of interventional radiology.

The oral abstract presentation, titled "Imaging Features in Patients Undergoing Liver RFA Plus Heat Deployed Nanoparticles," will report the unique imaging features suggesting improvement in thermal ablation volume with the addition of ThermoDox. The potential clinical significance of these findings support the randomized study in final planning by Celsion.

read the full text: http://www.ad-hoc-news.de/CorporateNews/en/14274894/Celsion-Corporation-Announces-Liver-Cancer-Abstract-Accepted